araag2/HINT huggingface dataset:
Clinical trial NCT02079909 (phase 2, status: completed)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: t-817ma-h, t-817ma-l, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female (post-menopausal or surgically sterile)

          -  Patients with Mild to moderate Alzheimer's disease who are receiving donepezil
             (Aricept®) or rivastigmine transdermal system (Exelon® Patch), . Memantine (Namenda®)
             is allowed only when prescribed in combination with donepezil or rivastigmine
             transdermal system.

          -  Age 55 to 85 inclusive

          -  Patients must be living in the community

          -  Patients must have an eligible informant or study partner (caregiver)

          -  Patients and eligible informant or study partner (caregiver) must be able to read and
             understand English.

          -  Informed consent obtained from both the patient and the caregiver

        Exclusion Criteria:

          -  Patients with clinically significant cardiac, hepatic or renal impairment

          -  Patient have a dementia not of the Alzheimer's type etc (According to the protocol)

          -  Patients who are taking any drug other than donepezil or rivastigmine transdermal
             system for Alzheimer's disease, including olal rivastigmine (Exelon®), galantamine
             (Razadyne®)
Clinical trial NCT02083653 (phase 2, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: sym004 (12 mg/kg), sym004 (9/6 mg/kg), fluorouracil (5-fu), capecitabine
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent obtained before undergoing any study-related activities

          -  Male or female, at least 18 years of age

          -  Subjects with histologically or cytologically confirmed mCRC, Kirsten rat sarcoma
             wild-type (KRAS WT) at initial diagnosis

          -  Failure of or intolerance to 5-FU, Oxaliplatin, and Irinotecan

          -  Acquired resistance to marketed anti-EGFR mAbs as defined in the protocol

          -  Measurable disease defined as one or more target lesions according to RECIST

          -  Life expectancy of at least 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Pretreatment with regorafenib.

          -  Subjects who in the opinion of the subject and investigator would benefit more from
             regorafenib treatment (except where regorafenib is not reimbursed in the country)

          -  Skin rash Common Terminology Criteria for AEs (CTCAE) Grade greater than 1 from
             previous anti-EGFR therapy at time of randomization

          -  Magnesium less than 0.9 milligram per deciliter (mg/dL)

          -  Known hypersensitivity to any of the treatment ingredients. Known previous Grade 3-4
             infusion related reactions with anti-EGFR mABs

          -  Other protocol defined exclusion criteria could apply
Clinical trial NCT02086786 (phase 2, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: risperidone ism
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          1. Capable of providing informed consent.

          2. Male or female aged ≥18 years to ≤65 years.

          3. Current diagnosis of schizophrenia, according to Diagnostic and Statistical Manual

          4. Body mass index (BMI) ≥17 kg/m2 but ≤35 kg/m2.

          5. Medically stable over the last month, and psychiatrically stable

          6. On oral stable dosage of risperidone ≥4 mg daily as maintenance therapy.

          7. Total score ≤70 on the Positive and Negative Syndrome Scale.

          8. Using a medically accepted contraceptive method

          9. Agrees to washout all prohibited medications prior to baseline (day -1)

        Exclusion Criteria:

          1. Informed consent obtained from a third party.

          2. Prisoners or patients who are compulsorily detained.

          3. Females who are breast-feeding and/or who have a positive pregnancy test.

          4. Presence of an uncontrolled, unstable clinically significant medical condition.

          5. Positive serology for Hepatitis B, Hepatitis C or anti-HIV 1 and 2 at screening.

          6. History of neuroleptic malignant syndrome.

          7. Current or past history of tardive dyskinesia.

          8. Positive urine drug or alcohol screen finding.

          9. Risk of committing self-harm or harm based on Columbia Suicidal Rating Scale.

         10. Taking more than one antidepressant.

         11. Use of depot antipsychotics within the last three months.

         12. Use of strong or moderate cytochrome P450 isoenzyme 3A4inducers

         13. Use of electroconvulsive therapy (ECT) within the last three months.

         14. Receipt of any investigational drugs within the last three months.

         15. Known or suspected allergy or hypersensitivity to risperidone

         16. Previous non-responder to risperidone treatment.
Clinical trial NCT02087943 (phase 2, status: completed)
Conditions: dermatitis, atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: apremilast, apremilast, placebo, placebo
SMILES: [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, [H][C@](CS(C)(=O)=O)(N1C(=O)C2=C(C1=O)C(=CC=C2)N=C(C)O)C1=CC(OCC)=C(OC)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Males or females, aged ≥ 18 years (≥ 20 for Japanese subjects) at the time of consent.

          2. Have a diagnosis of atopic dermatitis for ≥ 12 months.

          3. Have moderate to severe atopic dermatitis which is considered inappropriate for
             topical therapy or which cannot be adequately controlled by topical therapy.

          4. Meet the laboratory criteria as defined per protocol

          5. Females of Childbearing Potential (FCBP) must have a negative pregnancy test at
             Screening and Baseline. Sexually active FCBP must use one of the approved
             contraceptive options required per protocol while on and for at least 28 days after
             the last dose of study medication

          6. Male subjects (including those who have had a vasectomy) who engage in activity in
             which conception is possible must use barrier contraception while on and for at least
             28 days after the last dose of study medication.

        Exclusion Criteria:

          1. Active tuberculosis (TB) or a history of inadequately treated tuberculosis.

          2. Positive for hepatitis B surface antigen or hepatitis C antibody

          3. Pregnant or breast feeding

          4. History of allergy to any component of the study medication.

          5. Active skin infection requiring systemic antimicrobials at Baseline.
Clinical trial NCT02088541 (phase 2, status: completed)
Conditions: acute myeloid leukemia (aml)
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: selinexor, hydroxyurea, ara-c
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F, NC(=O)NO, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 60 years with relapsed or refractory AML of any type except for acute
             promyelocytic leukemia (APL; AML M3), after at least 1 prior AML therapy , who have
             never undergone, and who are not currently eligible for, stem cell transplantation,
             and are currently deemed unfit for intensive chemotherapy.

          -  Eastern Cooperative Oncology Group (ECOG) ≤ 2.

          -  Must have available archival or recently acquired bone marrow biopsy/aspiration or
             tumor tissue for central review to be eligible.

          -  Relapsed or refractory AML, defined as either: recurrence of disease after a complete
             remission (CR), or failure to achieve CR with initial therapy.

          -  Must have received at least 1 prior line of AML therapy given at standard doses and
             must have progressed after their most recent therapy. Prior therapy must have
             included: a hypomethylating agent with at least 2 cycles.

          -  At least 2 weeks must have elapsed since the last anti-leukemia treatment (with the
             exception of hydroxyurea) before first dose in this study.

        Exclusion Criteria:

          -  Treatment with any investigational agent within 3 weeks prior to first dose in this
             study.

          -  Presence of central nervous system (CNS) leukemia.

          -  In blast transformation of chronic myeloid leukemia (CML). Prior myelodysplastic
             syndrome (MDS) is acceptable; prior treatment for MDS does not count as an AML
             therapy.

          -  Major surgery within 2 weeks of first dose of study drug. Participants must have
             recovered from the effects of any surgery performed greater than 2 weeks previously.

          -  Concurrent active malignancy under treatment.

          -  Known active hepatitis B virus (HBV) or C virus (HCV) infection; or known to be
             positive for HCV ribonucleic acid (RNA) or HBsAg (HBV surface antigen).

          -  Known HIV infection.

          -  Unable to swallow tablets, or participants with malabsorption syndrome, or any other
             disease significantly affecting gastrointestinal function.

          -  Participants whose AML is classified as favorable according to the European
             LeukemiaNet (ELN) disease risk assessment.
Clinical trial NCT02091752 (phase 2, status: terminated)
Conditions: primary myelofibrosis
ICD codes: D75.81, C94.41, C94.42, C94.40
Drugs: ruxolitinib
SMILES: N#CC[C@H](C1CCCC1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1
Reason stopped: 
    the study was terminated due to low enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Confirmed diagnosis of PMF, PPV MF or PET-MF, irrespective of JAK2 mutational status
             according to the 2008 revised International Standard Criteria

          -  Peripheral blast count < 10%

          -  Requires therapy for MF in the opinion of the investigator

          -  Received prior monotherapy treatment with ruxolitinib for at least 12 consecutive
             weeks and experienced treatment interruption because of lossof response or adverse
             event

          -  Patients adhering to the Screening phase assessments and undergoing a a
             ruxolitinib-free washout period of a minimum of 1 week and a maximum of 8 weeks

          -  ECOG performance status 0, 1, 2, or 3

          -  Adequate bone marrow function

          -  Written informed consent

        Exclusion Criteria:

          -  Patients not initially responding (primary resistance) to ruxolitinib therapy

          -  Patients who underwent a splenectomy or spleen radiation

          -  Patients currently scheduled for bone marrow transplant

          -  Patients who have discontinued ruxolitinib < 14 days prior to screening

          -  Patients who are not able to receive a starting dose of ruxolitinib of at least 15 mg
             total daily dose

          -  Leukemic transformation

          -  Inadequate renal function

          -  Presence of clinically meaningful active bacterial, fungal, parasitic or viral
             infection which requires therapy

          -  Previous history of Progressive Multifocal Leuko-encephalopathy (PML)

          -  Clinically significant cardiac disease or significant concurrent medical condition
Clinical trial NCT02092935 (phase 2, status: completed)
Conditions: clostridium difficile infection
ICD codes: A05.2, A04.71, A04.72, B96.7
Drugs: smt19969, vancomycin
SMILES: CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1[C@@H](C)OC(=O)[C@H](CC(=O)C2=C(N)C=CC=C2)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCN)NC(=O)CNC1=O)[C@H](C)CC(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Informed consent

          -  Clinical diagnosis of CDAD plus laboratory diagnostic test

          -  No more than 24 hrs antimicrobial treatment for current CDAD episode

          -  No more than 3 episodes of CDAD in prior 12 months

          -  No previous episode of CDAD within 30 days of study enrollment

          -  Female subjects of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  Life-threatening or fulminant colitis

          -  Concurrent use of antibiotics or any other treatments for CDAD

          -  History of inflammatory bowel disease (ulcerative colitis, Crohn's disease)

          -  Participation in other Clinical research studies within one month of screening
Clinical trial NCT02094365 (phase 2, status: completed)
Conditions: respiratory syncytial virus infections
ICD codes: R09.2, A15.7, A15.8, A15.9, J98.9, R06.03, J12.1
Drugs: als-008176, vehicle
SMILES: CC1=CC(O)=CC(C)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18 to 45 years, inclusive.

          -  In good health with no history of major medical conditions

          -  A total body weight ≥ 50 kg and a body mass index (BMI) of > 18kg/m2.

        Exclusion Criteria:

          -  Acute or chronic medical illness

          -  Positive for Human Immunodeficiency Virus, Hepatitis B or C

          -  Nose or nasopharynx abnormalities

          -  Abnormal lung function
Clinical trial NCT02094443 (phase 2, status: completed)
Conditions: hepatitis c, liver disease
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9, K76.9, K71.8, K70.9, K71.9, K75.9, P78.84, Q44.6
Drugs: alisporivir, ribavirin
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O)C(C)C, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          1. Written informed consent must be obtained before any assessment is performed

          2. Participants with HCV genotype 2 or 3 infection who have previously failed interferon
             therapy or are intolerant or unable to take interferon

          3. Males or females aged ≥18 years

          4. Diagnosed Chronic hepatitis C virus infection

        Exclusion criteria:

          1. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of that medication before enrollment

          2. History of hypersensitivity to any of the study drugs or to drugs of similar chemical
             classes

          3. Hepatitis B surface antigen (HBsAg) positive

          4. Human immunodeficiency virus (HIV) positive

        Other protocol-defined inclusion/exclusion criteria apply.
Clinical trial NCT02094651 (phase 2, status: withdrawn)
Conditions: autism
ICD codes: Z13.41
Drugs: divalproex sodium
SMILES: CCCC(CCC)C(O)=O
Reason stopped: 
    no eligible patients were enrolled
  
Eligibility criteria:

        Inclusion Criteria:

          1. Male or female patients aged 4 to 10 years.

          2. Diagnosis of with ASD (Autistic Disorder, Asperger's Disorder, or pervasive
             developmental disorder (PDD-NOS).

          3. Frequent epileptiform discharges on EEG (defined as spikes, spike wave, and sharp
             waves occurring at greater than 15 events per hour).

          4. Intelligence quotient (IQ) range 40 to 100.

          5. Weight > or = 12.5 kg.

          6. English speaking families

        Exclusion Criteria:

          1. History of epilepsy, known neurogenetic disorder or chromosomal abnormalities with
             high rates of epilepsy (15q duplication syndrome, 16p deletion/duplication syndrome,
             Fragile X, tuberous sclerosis complex), or structural brain lesion (prior stroke,
             migrational defects, brain malformations).

          2. The presence of a severe epileptiform EEG on the sleep EEG referred to as electrical
             status epilepticus in sleep (ESES) in sleep

          3. Previous treatment with divalproex sodium that is any one of the following:

               -  of greater than 6 months duration

               -  within the last 12 months

               -  that was associated with significant side effects leading to termination of
                  treatment

          4. Children who have had general anesthesia within the six months or sedation within 2
             weeks of study enrollment.

          5. Recent (less than two months prior to study entry) initiation of a behavioral therapy
             program or new psychotropic medication, or the plan to change or start a new therapy.

          6. Presence of medical condition, such as carnitine deficiency, urea cycle disorder or
             other metabolic disorder that would be a contraindication to divalproex sodium usage.

          7. Presence of a significant untreated medical problem (obstructive sleep apnea, restless
             legs syndrome, GERD, etc.) which may have significant impact on sleep study measures.

          8. Renal, hepatic, pancreatic, or hematologic dysfunction as evidenced by values above
             upper limits of normal for BUN/creatinine, or values twice the upper limit of normal
             for serum transaminases (ALT/SGPT, AST/SGOT), values twice the upper limit of normal
             for serum lipase and amylase, platelets <80,000 /mcL, WBC<3.0 103 /mcL.

          9. Concomitant use of medication contraindicated with divalproex sodium including
             topiramate, lamotrigine, and drugs that inhibit cytochrome p450 enzymes.

         10. Behavioral management issues (e.g. self-injury, aggressiveness) severe enough to be of
             safety concerns (to subject and/or staff).

         11. Absence of primary care physician.
Clinical trial NCT02096133 (phase 2, status: terminated)
Conditions: multiple sclerosis
ICD codes: G35, C81.18
Drugs: cholecalciferol
SMILES: CC(C)CCC[C@@H](C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C
Reason stopped: 
    difficulties with inclusion
  
Eligibility criteria:

        Inclusion Criteria:

          -  Female

          -  Relapsing Remitting MS

          -  At start of study > 6 weeks in clinical remission of disease

          -  Age > 18 years.

          -  Premenopausal

          -  Treated with either no immune-modulating treatment, or the currently registered MS
             modulating treatments: Interferon beta 1a (Rebif®), Interferon Beta 1b (Betaferon® or
             Avonex®), Glatiramer Acetate (Copaxone®), dimethylfumarate (Tecfidera®), teriflunomide
             (Aubagio®)) or fingolimod (Gilenya®).

        Exclusion Criteria:

          -  Any contraindication to vitamin D according to Summary of Product Characteristics:
             Hypercalcaemia, hypervitaminosis D, nephrolithiasis, diseases or conditions resulting
             in hypercalcaemia and/or hypercalciuria (incl. primary hyperparathyroidism), severe
             renal impairment .

          -  Use of dexamethasone or other systemic glucocorticosteroids <2 months prior to first
             study visit

          -  Supplementation of >=1000 IU/d (25µg) vitamin D2 or D3

          -  Medical history of disturbed vitamin D/ calcium metabolism other than low intake

          -  Present clinical (major)depression

          -  Present treatment with anti-depressants, benzodiazepines, or neuroleptics.

          -  Treatment with high-dose dexamethasone for MS exacerbation during study.

          -  Pregnancy or the intention to become pregnant during the study period.
Clinical trial NCT02096354 (phase 2, status: active, not recruiting)
Conditions: colorectal neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: rrx-001, regorafenib, irinotecan
SMILES: [O-][N+](=O)C1(CN(C1)C(=O)CBr)[N+]([O-])=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=CC=CC=C4N=C13)C2=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum;

          -  Subject must have received at least oxaliplatin-, and irinotecan-based regimens with
             bevacizumab and with, cetuximab or panitumumab if KRAS wildtype and are refractory to
             irinotecan;

          -  Subject has measurable disease by radiographic techniques (computerized tomography
             [CT] or magnetic resonance imaging [MRI]);

          -  Subjects with a history of brain metastasis are eligible for the study as long as they
             meet all the following criteria: their brain metastases have been treated, they have
             no evidence of progression or hemorrhage after treatment, have been off dexamethasone
             for 4 weeks prior to first study drug administration, and have no ongoing requirement
             for dexamethasone or anti-epileptic drugs;

          -  Life expectancy of at least 12 weeks

          -  Subject's Eastern Cooperative Group (ECOG) performance status is 0 or 1;

          -  Adequate organ function

          -  Fertile subjects must use effective contraception during the course of the study and
             for 30 days following withdrawal from the study;

        Exclusion Criteria:

          -  Clinically significant cardiovascular disease;

          -  Unresolved toxicity higher attributed to any prior therapy/procedure excluding
             alopecia, hypothyroidism and oxaliplatin- induced neurotoxicity ≤ Grade 2 for at least
             14 days;

          -  Evidence or history of tendency or predisposition to active bleeding. Any hemorrhage
             or bleeding event of Grade 3 or higher within 4 weeks of start of study medication;

          -  Symptoms or signs of active brain metastases;

          -  History of an allergic reaction or intolerance to irinotecan

          -  Hepatic encephalopathy

          -  Cholangitis that required treatment or intervention within 4 weeks of study enrollment

          -  Concurrent anticancer therapy or any cytotoxic therapy within 1 month prior to Day 1.
             Corticosteroid therapy is not allowed except on dosing days;

          -  Subject has previously received regorafenib;

          -  Clear contraindication for systemic corticosteroids (diabetes mellitus is not per se a
             clear contraindication);

          -  Severe hypoalbuminemia (albumin < 3.0 g/dL);

          -  Subjects who are pregnant or lactating or who are planning to become pregnant during
             the course of the study are excluded.
Clinical trial NCT02098473 (phase 2, status: completed)
Conditions: eosinophilic esophagitis
ICD codes: K20.0
Drugs: rpc4046, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histologic evidence of EoE

          -  Clinical symptoms of EoE including dysphagia

        Exclusion Criteria:

          -  Primary causes of esophageal eosinophilia other than EoE